IL305317B2 - Compositions and methods for modulating hair growth - Google Patents

Compositions and methods for modulating hair growth

Info

Publication number
IL305317B2
IL305317B2 IL305317A IL30531723A IL305317B2 IL 305317 B2 IL305317 B2 IL 305317B2 IL 305317 A IL305317 A IL 305317A IL 30531723 A IL30531723 A IL 30531723A IL 305317 B2 IL305317 B2 IL 305317B2
Authority
IL
Israel
Prior art keywords
compound
nmr
mhz
alkyl
acid
Prior art date
Application number
IL305317A
Other languages
English (en)
Hebrew (he)
Other versions
IL305317B1 (en
IL305317A (en
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IL305317A publication Critical patent/IL305317A/en
Publication of IL305317B1 publication Critical patent/IL305317B1/en
Publication of IL305317B2 publication Critical patent/IL305317B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A61K8/70—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL305317A 2017-06-30 2018-06-29 Compositions and methods for modulating hair growth IL305317B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527775P 2017-06-30 2017-06-30
US201862654095P 2018-04-06 2018-04-06
PCT/US2018/040385 WO2019006359A1 (en) 2017-06-30 2018-06-29 COMPOSITIONS AND METHODS FOR MODULATION OF HAIR GROWTH

Publications (3)

Publication Number Publication Date
IL305317A IL305317A (en) 2023-10-01
IL305317B1 IL305317B1 (en) 2025-07-01
IL305317B2 true IL305317B2 (en) 2025-11-01

Family

ID=64742233

Family Applications (3)

Application Number Title Priority Date Filing Date
IL305317A IL305317B2 (en) 2017-06-30 2018-06-29 Compositions and methods for modulating hair growth
IL271443A IL271443B2 (en) 2017-06-30 2018-06-29 Compositions and methods for modulating hair growth
IL321754A IL321754A (en) 2017-06-30 2018-06-29 Compositions and methods for modulating hair growth

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL271443A IL271443B2 (en) 2017-06-30 2018-06-29 Compositions and methods for modulating hair growth
IL321754A IL321754A (en) 2017-06-30 2018-06-29 Compositions and methods for modulating hair growth

Country Status (15)

Country Link
US (5) US11312714B2 (https=)
EP (1) EP3644989A4 (https=)
JP (3) JP7221227B2 (https=)
KR (3) KR102642823B1 (https=)
CN (2) CN116120314A (https=)
AR (1) AR114075A1 (https=)
AU (3) AU2018294351B2 (https=)
CA (1) CA3067746A1 (https=)
CL (1) CL2019003886A1 (https=)
EA (1) EA202090179A1 (https=)
IL (3) IL305317B2 (https=)
MX (2) MX2019015475A (https=)
PE (1) PE20200743A1 (https=)
PH (1) PH12019502776A1 (https=)
WO (1) WO2019006359A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110300583A (zh) 2017-02-24 2019-10-01 加利福尼亚大学董事会 利用mpc1抑制剂促进毛发生长的组合物和方法
KR102642823B1 (ko) 2017-06-30 2024-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
CN112153957B (zh) * 2018-04-13 2023-12-26 北卡罗来纳州立大学 微针贴剂促进毛发生长的用途
AR117555A1 (es) * 2019-01-02 2021-08-11 Univ California Composiciones y métodos para modular el crecimiento del cabello
FR3105222B1 (fr) * 2019-12-20 2022-06-03 Nunii Laboratoire Inhibiteur du transporteur MCT7/SLC16A6 pour son utilisation pour la régulation de la pigmentation cutanée et une composition comprenant ledit inhibiteur
AU2020407122A1 (en) * 2019-12-20 2022-06-23 The Regents Of The University Of California Synthesis of compounds to promote hair growth
WO2021253013A2 (en) * 2020-06-12 2021-12-16 Rekindle Therapeutics Inc. Modulators of e3 ligases
US20240327400A1 (en) * 2020-06-30 2024-10-03 The Regents Of The University Of California Compositions and methods for modulating hair growth
EP4172159A4 (en) 2020-06-30 2024-01-10 The Regents of the University of California Compositions and methods for modulating hair growth
IL314012A (en) * 2021-12-29 2024-08-01 Pelage Pharmaceuticals Inc Preparations for the treatment of baldness
MX2024008333A (es) 2021-12-29 2024-08-30 Pelage Pharmaceuticals Inc Compuestos para tratamiento de pérdida de cabello.
WO2023191515A1 (ko) * 2022-03-29 2023-10-05 연세대학교 산학협력단 인디루빈 유도체 및 대사활성화제를 포함하는 탈모 방지 또는 발모 촉진용 조성물
KR20250123928A (ko) * 2022-12-27 2025-08-18 펠라지 파마슈티컬스, 인크. 탈모 치료용 화합물
CN116251086A (zh) * 2023-02-15 2023-06-13 江西中医药大学 乳酸及其衍生物在促毛发生长及缓解脱发中的应用
CN121005682A (zh) * 2024-05-24 2025-11-25 上海医药工业研究院有限公司 一种2-苯基-吡咯类化合物、其制备方法及其应用
WO2026067664A1 (zh) * 2024-09-26 2026-04-02 海思科医药集团股份有限公司 一种氰基取代的杂环衍生物及其在医药上的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124354A (en) * 1989-06-14 1992-06-23 Chesebrough Pond's Usa Co., Division Of Conopco, Inc. Cosmetic composition containing an aryl-substituted ethylene
US5397787A (en) * 1992-12-23 1995-03-14 Farmitalia Carlo Erba S.R.L. Vinylene-azaindole derivatives
US6541507B1 (en) * 1999-07-16 2003-04-01 Societe L'oreal S.A. Indolecarboxylic compounds for inducing/stimulating hair growth and/or retarding hair loss

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPH0235746B2 (ja) 1983-03-07 1990-08-13 Sagami Chem Res 33chikantetorafuruoroindoorujudotai
US4680413A (en) * 1986-01-17 1987-07-14 Nippon Soda Co., Ltd. Process for the production of 3-phenyl-4-cyanopyrroles
GB9014221D0 (en) 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
GB9023585D0 (en) 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
CA2406871A1 (en) 2000-02-23 2001-08-30 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
BR0210744A (pt) 2001-07-17 2004-07-20 N Gene Res Lab Inc Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes
JP2006519791A (ja) 2003-03-13 2006-08-31 ノボ　ノルディスク　アクティーゼルスカブ 新規なｎｐｈインスリン製剤
JP2007512263A (ja) 2003-11-25 2007-05-17 ノボ　ノルディスク　アクティーゼルスカブ 化学的脱共役剤として使用するためのインドール誘導体
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
US20050277784A1 (en) 2004-06-14 2005-12-15 Wyeth Processes for the preparation of 2-cyano-3-naphthalene-1-yl-acrylic acid alkyl or benzyl esters
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
ES2614113T3 (es) 2004-09-17 2017-05-29 Biomas Ltd. Uso de tricloro (dioxietilen-O,O’) telurato de amonio (AS101) para la inhibición de la enzima convertidora de interleucina-1 beta
JP4974903B2 (ja) 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
CA2611577A1 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
CN102206216B (zh) 2005-06-22 2014-11-12 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
GB0525337D0 (en) 2005-12-13 2006-01-18 Novartis Ag Organic compounds
US8343962B2 (en) 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
PE20080767A1 (es) 2006-08-31 2008-08-08 Smithkline Beecham Corp Derivados de acido 1-indol-2-carboxilico como moduladores de ppar
US20080064765A1 (en) 2006-09-11 2008-03-13 Jacob Birnbaum Novel hair growth compositions and methods for treating hair loss or related claims
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8563500B2 (en) 2007-09-05 2013-10-22 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
JP5529743B2 (ja) 2007-11-05 2014-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 選択的１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤としての７−アザインドール誘導体
TWI461423B (zh) * 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
WO2011123788A1 (en) 2010-04-01 2011-10-06 Duke University Compositions and methods for the treatment of cancer
EP2648676A4 (en) 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
RU2669695C2 (ru) * 2011-12-22 2018-10-15 Конекшис Лайф Сайенсиз Пвт. Лтд. Циклические амидные производные как ингибиторы 11-бета-гидроксистероид-дегидрогеназы и их применение
US20150099790A1 (en) * 2012-05-10 2015-04-09 University Of Utah Research Foundation Compositions and methods for modulating mitochondrial pyruvate carrier activity
WO2013185214A1 (en) 2012-06-11 2013-12-19 Universite Laval Pla2g7/lp-pla2 as biomarker and therapeutic target in the prevention and treatment of calcific aortic valve disease
WO2013188554A1 (en) 2012-06-12 2013-12-19 The Regents Of The University Of California Fluorination of aryl compounds
WO2014113467A1 (en) 2013-01-15 2014-07-24 Board Of Regents, The University Of Texas System Stat3 inhibitor
WO2014207213A1 (en) 2013-06-28 2014-12-31 Medizinische Universität Innsbruck Novel inhibitors of protein kinase c epsilon signaling
US9714240B2 (en) 2013-09-17 2017-07-25 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
WO2015049365A2 (en) * 2013-10-03 2015-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
US9499551B2 (en) 2014-01-24 2016-11-22 Confluence Life Sciences, Inc. Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases
EP3455207A4 (en) 2016-05-12 2019-10-09 Regents of the University of Minnesota INDOL AND INDAZOCYANOCINNAMATE COMPOUNDS AND THERAPEUTIC USES THEREOF
KR20190058494A (ko) 2016-08-26 2019-05-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 모낭 줄기 세포 활성화 및 모발 성장
WO2018039612A1 (en) * 2016-08-26 2018-03-01 The Regents Of The University Of California Compositions and methods for promoting hair growth with mpc1 inhibitors
CN110446503A (zh) 2016-12-22 2019-11-12 马福制药公司 磷酸二酯酶抑制剂及微生物治疗方法
CN110300583A (zh) 2017-02-24 2019-10-01 加利福尼亚大学董事会 利用mpc1抑制剂促进毛发生长的组合物和方法
CN106880693A (zh) 2017-03-22 2017-06-23 广州国草夏方生物科技有限公司 一种治疗脂溢性脱发的生发液组合物及其制备方法
KR102642823B1 (ko) 2017-06-30 2024-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
KR20200062242A (ko) 2017-09-29 2020-06-03 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하는 조성물 및 방법
AR117555A1 (es) 2019-01-02 2021-08-11 Univ California Composiciones y métodos para modular el crecimiento del cabello
US20220079899A1 (en) 2019-01-14 2022-03-17 The Regents Of The University Of California Compositions and methods for treating ocular conditions
US20220079900A1 (en) 2019-01-14 2022-03-17 The Regents Of The University Of California Compositions and methods for treating cardiac injury
AU2020407122A1 (en) 2019-12-20 2022-06-23 The Regents Of The University Of California Synthesis of compounds to promote hair growth
EP4172159A4 (en) 2020-06-30 2024-01-10 The Regents of the University of California Compositions and methods for modulating hair growth
US20240327400A1 (en) 2020-06-30 2024-10-03 The Regents Of The University Of California Compositions and methods for modulating hair growth

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124354A (en) * 1989-06-14 1992-06-23 Chesebrough Pond's Usa Co., Division Of Conopco, Inc. Cosmetic composition containing an aryl-substituted ethylene
US5397787A (en) * 1992-12-23 1995-03-14 Farmitalia Carlo Erba S.R.L. Vinylene-azaindole derivatives
US6541507B1 (en) * 1999-07-16 2003-04-01 Societe L'oreal S.A. Indolecarboxylic compounds for inducing/stimulating hair growth and/or retarding hair loss

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EL MAATOUGUI ABDELAZIZ ET AL:, SUPPORTED TBD-ASSISTED SOLUTIONPHASE DIVERSIFICATION OF FORMYL-AZA-HETEROCYCLES THROUGH ALKYLATION-KNOEVENAGEL ONE POT SEQUENCES, 1 August 2011 (2011-08-01) *
LIU HAILONG ET AL:, IDENTIFICATION OF NOVEL THIADIAZOLOACRYLAMIDEANALOGUES AS INHIBITORS OF DENGUE-2 VIRUS NS2B/NS3 PROTEASE, 5 October 2014 (2014-10-05) *
MAGAR ET AL:, SYNTHESIS OF SOME NOVEL 3-SUBSTITUTED INDOLE DERIVATIVESUSING POLYAMINE FUNCTIONALIZED HETEROGENEOUS CATALYST, 1 January 2015 (2015-01-01) *
YAKHONTOV L N ET AL:, PYRROLO[2,3-B]PYRIDINE DERIVATIVES (7-AZAINDOLES)VIII. SYNTHESIS AND SOME REACTIONS OF 4-METHYL-L- PHENYL-1 H-4-METHYL-1-PHENYL-1 H-PYRROL0[2, 3-B]PYRIDINE-3- CARBOXALDEHYDEL, 1 August 1964 (1964-08-01) *

Also Published As

Publication number Publication date
MX2022007823A (es) 2022-07-19
US12227503B2 (en) 2025-02-18
MX2019015475A (es) 2020-02-19
US11472804B2 (en) 2022-10-18
US20220153738A1 (en) 2022-05-19
NZ759233A (en) 2023-08-25
AR114075A1 (es) 2020-07-15
WO2019006359A1 (en) 2019-01-03
AU2025202961A1 (en) 2025-05-15
IL271443B2 (en) 2024-01-01
KR102642823B1 (ko) 2024-03-04
BR112019026080A8 (pt) 2022-11-22
BR112019026080A2 (pt) 2020-06-30
CN110944634A (zh) 2020-03-31
IL271443A (en) 2020-01-30
CA3067746A1 (en) 2019-01-03
US11312714B2 (en) 2022-04-26
US20230114220A1 (en) 2023-04-13
IL321754A (en) 2025-08-01
AU2023201669B2 (en) 2025-01-30
US11787804B2 (en) 2023-10-17
US20250304579A1 (en) 2025-10-02
JP2020526484A (ja) 2020-08-31
CL2019003886A1 (es) 2020-05-22
KR20200022480A (ko) 2020-03-03
EA202090179A1 (ru) 2020-04-24
JP2023061995A (ja) 2023-05-02
CN116120314A (zh) 2023-05-16
US20240025895A1 (en) 2024-01-25
EP3644989A1 (en) 2020-05-06
IL305317B1 (en) 2025-07-01
KR20240033119A (ko) 2024-03-12
KR20250151619A (ko) 2025-10-21
AU2018294351A1 (en) 2019-12-05
JP7221227B2 (ja) 2023-02-13
EP3644989A4 (en) 2021-07-14
KR102872871B1 (ko) 2025-10-16
US20200157093A1 (en) 2020-05-21
PH12019502776A1 (en) 2020-10-26
AU2023201669A1 (en) 2023-04-13
PE20200743A1 (es) 2020-07-24
AU2018294351B2 (en) 2022-12-22
JP2025102814A (ja) 2025-07-08
IL305317A (en) 2023-10-01
IL271443B1 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
US11787804B2 (en) Compositions and methods for modulating hair growth
AU2019418584A1 (en) Compositions and methods for modulating hair growth
CA3124820C (en) Compositions and methods for modulating hair growth
BR122022021324B1 (pt) Uso de compostos inibidores do transportador de piruvato mitocondrial para tratar calvície ou alopécia
BR112019026080B1 (pt) Composto capaz de inibir o transportador de piruvato mitocondrial e composição farmacêutica que compreende o mesmo
EA051372B1 (ru) Композиции и способы модуляции роста волос
HK40063658A (en) Compositions and methods for modulating hair growth
NZ759233B2 (en) Compositions and methods for modulating hair growth
HK40026047A (en) Compositions and methods for modulating hair growth